New research shows that, given the choice, patients will now reach
for cannabis over prescription opioids, anti-depressants and sedatives,
such as Valium and Xanax.
Canada is one of the first nations to create a federal medical
cannabis program. As of August 2016, more than 65,000 patients were
receiving products from more than 30 federally-licensed medical cannabis producers.
Collecting Medical Cannabis Data
In order to asses the merit of the new federal program, professors at
the University of British Columbia (UBC) and the University of Victory
created a survey of 107 questions. These questions pertained to demographics, patterns of use and the cannabis substitution effect.
Two hundred and seventy one patients, all with prescriptions to
medical cannabis, responded to the survey. These individuals had a
wide range of conditions including chronic pain, metal health and
gastrointestinal issues, while also retaining prescriptions for many
other drugs.
“This study is one of the first to track medical cannabis use under the new system of licensed producers, meaning that all participants had physician authorization to access cannabis in addition to their prescription medicines,” says UBC Associate Professor Zach Walsh, co-author of the study. (source)
Survey Results
Well over half (63 percent) of all survey participants stated their
preference for cannabis over other prescription drugs. Of that 63
percent:
- 30% chose cannabis over prescription opioids (to treat pain),
- 16% chose cannabis over benzodiazepines (sedatives), and
- 12% chose cannabis over anti-depressants.
Philippe Lucas, the study lead, is the vice president of patient research at Tilray.
Tilray is a federally-authorized medical cannabis production and
research company. He suggests that patients are more likely to chose
cannabis over pharmaceutical drugs due to fewer side effects, better
symptom management, and the perception that cannabis is safer than
prescription drugs. (source)
The Future of Cannabis as a Substitution
Cannabis is a fairly new contender in the mainstream market
for prescription drugs. Therefore, there is still much research needed
to truly understand its effects.
“Further research into how well cannabis works compared to the accepted front-line treatments is warranted,” says Prof. Walsh. “Additionally, long-term research into the potential impact of the cannabis substitution on the quality of patients’ lives is ongoing.”
I find the idea of offering patients much safer alternatives to
standard chemical medications very appealing. Consequently, I sincerely
hope that more states across the United States pursue the use of medical
cannabis and that science helps us discover the true long-term benefits
of this plant.
0 comments:
Post a Comment